FFilingSight

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →

Intuitive Surgical Inc.

ISRGHealthcare

Generated Aug 19, 2026, 10:31 PM UTC

analytical score 7

ISRG (Intuitive Surgical Inc.) analytical snapshot. Revenue grew +20.5% YoY to $10.06B. 5-year revenue CAGR +12.0%; 10y CAGR +15.7%. Net margin at 28.38% (expanding ▲). Market cap $140.51B at $397.72 per share. Trailing P/E 50.54, P/S 13.96, P/B 7.73. EV/Operating income ≈ 46.76 (EV $137.75B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score 7 (data confidence 82%). Descriptive analytics from public filings — not investment advice.

Market cap
$140.51B
353.28M shares
Price
$397.72
NMS
P/E (ttm)
50.54
Revenue (FY)
$10.06B
YoY +20.5%
Net margin
28.38%
▲ 7.13pp
Free cash flow
$2.49B
24.75% margin
Risk level
Low

Free SEC analysis

— computed from SEC filings, free to read
Free previewRegulatory Analyst

Filings & Ownership

Regulatory Analyst
score 20Improving
80% conf

Latest annual report (10-K) filed Feb 3, 2026. Latest quarterly report (10-Q) filed Jul 21, 2026. 9 recent 8-K material-event filings in the index.

  • Latest annual report (10-K) filed Feb 3, 2026.
  • Latest quarterly report (10-Q) filed Jul 21, 2026.
  • 9 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference Intuitive Surgical Inc.; broad institutional reporting.
  • Recent filers include Saranac Partners Ltd, COATUE MANAGEMENT LLC, COATUE MANAGEMENT LLC.
  • 20 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 3, 2026
Annual report
Latest 10-Q
Jul 21, 2026
8-K (recent)
9
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
FilerFormFiled
Saranac Partners Ltd13F-HRDec 5, 2025
COATUE MANAGEMENT LLC13F-HRMay 15, 2025
COATUE MANAGEMENT LLC13F-HRAug 14, 2025
COATUE MANAGEMENT LLC13F-HRNov 14, 2025
COATUE MANAGEMENT LLC13F-HRMay 15, 2026
Recent 8-K material events
DateFormDescription
Jul 27, 20268-K8-K
Jul 16, 20268-K8-K
May 28, 20268-K8-K
May 4, 20268-K8-K
Apr 21, 20268-K8-K
Mar 2, 20268-K8-K
Jan 22, 20268-K8-K
Jan 14, 20268-K8-K
Sources:SEC EDGAR — Company FilingsSEC EDGAR — Full-Text Search
Free previewSEC Filing Analyst

SEC Filing Deep-Analysis

SEC Filing Analyst
score -15Deteriorating
68% conf

1 risk signal(s) detected from XBRL filing diff analysis. 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.

  • NEW: Restatement of financial statements in latest filing: The term "restatement of" "previously issued" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 5 filing(s).
  • Endogenous analysis: 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
  • 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • 1 new risk-language term(s) detected in filing text: Restatement of financial statements.
Revenue
$10.06B
+20.5% YoY
Gross profit
$6.64B
+17.9% YoY
Operating income
$2.95B
+25.4% YoY
Net income
$2.86B
+23.0% YoY
Operating cash flow
$3.03B
+25.5% YoY
Capex
$539.8M
-51.4% YoY
Total assets
$20.46B
+9.2% YoY
Total liabilities
$2.52B
+13.7% YoY
Filing quality score
78/100
4 new disclosures
SEC XBRL metric changes (latest annual vs prior)
MetricPrior yearLatest yearChange% Change
Revenue$8.35B$10.06B$1.71B+20.5%
Gross profit$5.63B$6.64B$1.01B+17.9%
Operating income$2.35B$2.95B$596.6M+25.4%
Net income$2.32B$2.86B$533.4M+23.0%
Operating cash flow$2.42B$3.03B$615.5M+25.5%
Capex$1.11B$539.8M$-571.4M-51.4%
Total assets$18.74B$20.46B$1.72B+9.2%
Total liabilities$2.21B$2.52B$303.4M+13.7%
Cash & equivalents$2.03B$3.37B$1.34B+66.1%
Stockholders equity$16.43B$17.82B$1.39B+8.5%
Inventory$1.49B$1.84B$352.8M+23.7%
Accounts receivable$1.23B$1.53B$301.9M+24.6%
R&D expense$1.15B$1.31B$166.5M+14.5%
SG&A expense$2.14B$2.38B$245.0M+11.4%
XBRL disclosure changes (new vs dropped concepts)
TypeConcepts
AddedBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets, BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue, ProceedsFromSaleOfOtherProductiveAssets, ShareRepurchaseProgramExciseTax
RemovedAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AcquisitionCosts, AllowanceForDoubtfulAccountsReceivableCurrent, BuildingsAndImprovementsGross, BusinessCombinationContingentConsiderationLiabilityCurrent, CapitalizedComputerSoftwareGross, CapitalizedContractCostAmortization, ConstructionInProgressGross, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit
Risk language in filing text (EDGAR full-text search)
TermSeverityRecentPriorStatus
Restatement of financial statementshigh50NEW
Impairment chargemedium52Ongoing
Restructuringmedium53Ongoing
Off-balance sheet arrangementsmedium52Ongoing
Related party transactionslow50NEW
Filing signal breakdown
Red flags: 1
Positive: 0
Watch: 0
Red flags
Positive
Watch
Sources:SEC EDGAR — Company Facts (XBRL)SEC EDGAR — Financial Reports
Free previewFundamentals Analyst

Fundamentals

Fundamentals Analyst
score 75Improving
80% conf

Revenue grew +20.5% YoY to $10.06B. 5-year revenue CAGR +12.0%; 10y CAGR +15.7%. Net margin at 28.38% (expanding ▲).

  • Revenue grew +20.5% YoY to $10.06B.
  • 5-year revenue CAGR +12.0%; 10y CAGR +15.7%.
  • Net margin at 28.38% (expanding ▲).
  • Return on equity 16.02%, ROA 13.96%, ROIC 16.53%.
  • Gross margin 66.00%, operating margin 29.27%.
  • Free cash flow margin 24.75% ($2.49B).
  • Net income up ▲ +23.0% YoY.
  • Asset turnover 0.48 — capital efficiency.
Revenue (FY)
$10.06B
YoY +20.5%
Net margin
28.38%
▲ 7.13pp
ROE
16.02%
ROA 13.96%
ROIC
16.53%
EPS (diluted)
$7.87
FY2025
Free cash flow
$2.49B
24.75% margin
Debt / equity
—
Cash $2.76B
Current ratio
4.96
Equity $18.17B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
FYRevenueRev YoYGross%Op%Net%FCFROE%
2024$8.35B+17.2%67.4628.1227.81$1.30B14.13
2025$10.06B+20.5%66.0029.2728.38$2.49B16.02
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
Quarter endRevenueYoYQoQNet margin
Sep 30, 2024$2.04B+16.9%—27.73%
Mar 31, 2025$2.25B+19.2%+10.6%30.99%
Jun 30, 2025$2.44B+21.4%+8.3%26.98%
Sep 30, 2025$2.51B+22.9%+2.7%28.12%
Mar 31, 2026$2.77B+23.0%+10.6%29.65%
Jun 30, 2026$2.89B+18.5%+4.4%28.29%
Sources:SEC EDGAR — Company Facts (XBRL)
+8 more years of history, charts & full breakdown Pro

Pro analysis — preview

— score, signals & key metrics shown; full reasoning locked

Valuation

Valuation Analyst
score -70Deteriorating
95% conf

Market cap $140.51B at $397.72 per share. Trailing P/E 50.54, P/S 13.96, P/B 7.73. EV/Operating income ≈ 46.76 (EV $137.75B).

  • Market cap $140.51B at $397.72 per share.
Market cap
$140.51B
353.28M shares
P/E (ttm)
50.54
P/S
13.96
P/B
7.73
EV
$137.75B
Intrinsic (DCF)
$173.42
-56.4% vs price
ProFull breakdown & reasoning locked

Price & Technicals

Technical Analyst
score -15Stable
85% conf

Price $397.72 — downtrend (below 200-DMA); 1-month momentum positive. RSI(14) 76.67 (overbought).

  • Price $397.72 — downtrend (below 200-DMA); 1-month momentum positive.
Price
$397.72
NMS
RSI(14)
76.67
50-DMA
$390.00
200-DMA
$474.77
Volatility (ann.)
36.92%
52w range
$328.57–$603.88
-34.1% from high
ProFull breakdown & reasoning locked

Macro & Rates

Macro Analyst
score 30Improving
80% conf

Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.

  • Market regime: Risk-on · Supportive.
GDP growth
1.50%
CPI (YoY)
+3.3%
Fed funds
3.63%
10Y yield
4.71%
10Y−2Y
0.46pp
Unemployment
4.10%
ProFull breakdown & reasoning locked

Risk Scorecard

Risk Analyst
score 24Improving
83% conf

Composite risk Low. Liquidity current ratio 4.96 (adequate). Earnings stability: net-margin stdev 3.50pp over 19y.

  • Composite risk: Low.
Risk level
Low
Debt / equity
—
Current ratio
4.96
Margin stdev
3.50pp
Cash / assets
13.22%
Liab / assets
12.35%
ProFull breakdown & reasoning locked

See the full picture behind every stock

Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.

Subscribe to ProCreate free account

3 sections free · 4 Pro previews · composite 7

Macro exposure

Defensive · Low sensitivity
Neutral

Macro regime: Risk-on · Supportive. Intuitive Surgical Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.

Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
15.84
Fed funds
3.63%
CPI YoY
+3.3%

Analytical read

deterministic preview

Revenue grew **+20.5%** YoY to $10.06B..

Risk
Low
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Open analytical workspace

Peer comparison

Defensive group

How ISRG stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.

CompanyScoreMacro
DexCom Inc. DXCM21Neutral
Bristol-Myers Squibb BMY19Neutral
Eli Lilly & Co. LLY17Neutral
HCA Healthcare HCA9Neutral
Gilead Sciences GILD8Neutral
Johnson & Johnson JNJ8Neutral
Abbott Laboratories ABT7Neutral
Biogen Inc. BIIB7Neutral
Intuitive Surgical Inc. ISRG● you7Neutral
Coca-Cola Co. KO6Neutral
Thermo Fisher Scientific TMO3Neutral
Regeneron Pharmaceuticals REGN3Neutral
Danaher Corp. DHR1Neutral
Merck & Co. MRK0Neutral
Zoetis Inc. ZTS0Neutral
Illumina Inc. ILMN0Neutral
Colgate-Palmolive CL-2Neutral
Vertex Pharmaceuticals VRTX-2Neutral
AbbVie Inc. ABBV-5Neutral
Procter & Gamble PG-7Neutral
CVS Health Corp. CVS-8Neutral
Mondelez International MDLZ-10Neutral
Amgen Inc. AMGN-10Neutral
Cigna Group CI-11Neutral
Kroger Co. KR-12Neutral
Costco Wholesale COST-14Neutral
Walmart Inc. WMT-14Neutral
Pfizer Inc. PFE-15Neutral
PepsiCo Inc. PEP-16Neutral
Sysco Corp. SYY-16Neutral
Hershey Co. HSY-17Neutral
Kimberly-Clark Corp. KMB-18Neutral
Moderna Inc. MRNA-21Neutral
UnitedHealth Group UNH-25Neutral